Drug intelligence / Profile preview

JN101

Development stage: Unknown
Lead developer: Jaan Biotherapeutics
Administration: Injection

Overview

JN101 is an investigational drug currently in a Phase 0 clinical study. It is being evaluated for its safety, tolerability, and anti-tumor effects in patients diagnosed with malignant solid tumors. The drug is administered via injection and is being studied in combination with radiotherapy. Development and clinical investigation involve Suzhou Jena Biotechnology Co., Ltd., Soochow University, and Lishui Central Hospital.

Targets

let-7a (Let-7a microRNA)let-7c (MicroRNA let-7c)

Beyond the preview

Go deeper on JN101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JN101.

Explore the full profile